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Although epithelial cell adhesion/activating molecule (EpCAM/CD326) is one of the first tumour-associated antigens identified, it has
never received the same level of attention as other target proteins for therapy of cancer. It is also striking that ever since its discovery
in the late 1970s the actual contribution of EpCAM to carcinogenesis remained unexplored until very recently. With a First
International Symposium on EpCAM Biology and Clinical Application this is now changing. Key topics discussed at the meeting were
the frequency and level of EpCAM expression on various cancers and its prognostic potential, the role of EpCAM as an oncogenic
signalling molecule for cancer cells, recent progress on EpCAM-directed immunotherapeutic approaches in clinical development and
the interaction of EpCAM with other proteins, which may provide a basis for a therapeutic window and repression of its growth-
promoting signalling in carcinoma. Future research on EpCAM may benefit from a unified nomenclature and more frequent exchange
among those who have been working on this cancer target during the past 30 years and will do so in the future.
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The two-day meeting gathered participants from academic
institutions, biotech, and pharmaceutical industry, and gave an
excellent opportunity and framework to review the progress on
epithelial cell adhesion and activating molecule (EpCAM) biology
and the development of novel EpCAM-directed immunotherapies.
In his introductory remarks, G Riethmueller (Munich, Germany)
pointed out that the first human tumour-associated antigen
identified with monoclonal antibodies (mAb) was in fact EpCAM
or 17-1A antigen (Herlyn et al, 1979). Moreover, the first mono-
clonal antibody ever applied for human cancer therapy was murine
mAb 17-1A recognising EpCAM (Sears et al, 1982, 1984). In 1994,
mAb17-1A (later named edrecolomab and Panorex
s) was also the
first to show clinical efficacy in a human cancer indication in terms
of prolonged overall survival (Riethmu ¨ller et al, 1994). It was then
almost 30 years after the first generation of an EpCAM-specific
monoclonal antibody that an international community gathered in
Bavaria to discuss for the first time the most recent advances in the
field of EpCAM research and clinical utility.
EpCAM has meanwhile advanced to an established epithelial cell
marker used in pathological examinations. Likewise, EpCAM can
now be considered to be one of the most frequently and most
intensely expressed tumour-associated antigens known. It is found
expressed on a great variety of human adenocarcinoma and
squamous cell carcinoma (Went et al, 2004). Very recent immuno-
histochemistry (IHC) studies analysed fairly large sample numbers
from patients with breast, prostate, ovarian, lung, colon, renal, and
gastric cancer (Spizzo et al, 2004, 2006b; Went et al, 2005, 2006).
These data impressively underscore the potential utility of EpCAM
as immunotherapeutic target for treatment of the most frequent
human cancers.
At least seven different immunotherapeutic approaches are
currently in clinical trials that target EpCAM (see Table 1). Some of
them have already progressed to the level of phase II and pivotal
trials, indicating that initial safety questions with EpCAM-directed
therapeutic approaches have been successfully addressed in
preceding phase 1 studies and that the assessment of clinical
efficacy is now of primary interest.
Only recently, research on EpCAM started to focus on its role in
carcinogenesis. In 2004, first evidence for a direct role of EpCAM
in growth-promoting nuclear signalling was reported (Munz et al,
2004). These data and results published by the group of Gillanders
(Osta et al, 2004) revived research on the biological function of
EpCAM, which is now delivering breakthrough results.
The present meeting review is focused on new data investigating
the significance of EpCAM for cancer biology and therapy, and
can therefore not adequately cover all presentations given at the
symposium. We apologise to those attendees whose presenta-
tions are not mentioned or not fully covered. The majority of the
meeting presentations can be viewed at www.epcam-symposium.de.
NEED FOR A COMMON NAME OF THE PROTEIN
The human EpCAM protein has plenty of synonyms, including
Ep-CAM, 17-1A, HEA125, MK-1, GA733-2, EGP-2, EGP34, KSA,
TROP-1, ESA, and KS1/4, among others. This is due to the fact that
the protein has been independently discovered many times as a
highly immunogenic tumour-associated antigen. With each dis-
covery, the antigen received the name of the respective monoclonal
antibody recognising it. Cloning of the EpCAM gene and respective
analyses of antigens finally, verified, in each case, their identity
Received 14 July 2006; revised 27 September 2006; accepted 10
October 2006; published online 9 January 2007
*Correspondence: Dr PA Baeuerle;
E-mail: Patrick.baeuerle@micromet-inc.com
British Journal of Cancer (2007) 96, 417–423
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
swith EpCAM. Nevertheless, different protein names are still being
used today, which makes it difficult even for the specialist to follow
the latest publications, whereas it is nearly impossible for the
nonspecialist to obtain a comprehensive picture of the properties
of this tumour-associated antigen and its therapeutic potential.
The attendees of the symposium therefore unanimously wish
to suggest to the scientific community to use for future reference
only one name for this protein. This name is proposed to be
EpCAM (without a dash) as an abbreviation for the ability of the
protein to act as an epithelial-specific cell adhesion molecule
(Litvinov et al, 1994) and activating molecule (Munz et al, 2004;
Osta et al, 2004). It is also suggested to add in brackets on the first
occurrence of the EpCAM name in a text the recently introduced
cellular differentiation (CD) marker nomenclature for EpCAM,
namely CD326.
EpCAM (CD326) is related to a protein called TROP-2 showing
approximately 50% sequence identity. Because TROP-2 is much
less investigated than EpCAM in terms of function and tissue
distribution, the attendees agreed that, for now EpCAM should not
be termed EpCAM-1, and TROP-2 not EpCAM-2, until this is
justified by further data supporting a similar function and tissue
tropism of the two proteins.
Recently, the gene for EpCAM was renamed from GA733-2 to
TACSTD1, the abbreviation for ‘tumour-associated calcium signal
transducer protein 1-precursor’. It is also suggested to abandon
this gene name as it does not properly reflect the function of the
encoded protein and to either revert to the previous gene name, or
adopt a new name, for example epcam.
EpCAM STRUCTURE AND FUNCTION
EpCAM is a type I membrane protein of 314 amino acids (aa) of
which only 26 aa are facing the cytoplasm. The extracellular
domain is believed to contain two epidermal growth factor (EGF)-
like domains. P Baeuerle (Carlsbad, USA) presented results
corroborating earlier reports showing that the second EGF-like
repeat of EpCAM is in fact a thyroglobulin (TY) repeat domain
(Linnenbach et al, 1989; Chong and Speicher, 2001) (Figure 1A).
Thyroglobulin domains are frequently mistaken as EGF-like
domains (Novinec et al, 2006). An accordingly revised structure
model for EpCAM is shown in Figure 1B, which also includes
additional features of EpCAM as reported during this symposium.
A common biological function of all TY domains investigated to
date is that they can potently inhibit cathepsins, a family of
cysteine proteases frequently produced by tumour cells and known
to be involved in metastasis (Nomura and Katunuma, 2005).
Ongoing studies are investigating a role of EpCAM as membrane-
bound protease inhibitor, a function that may serve to protect
tumour cells from their own secreted cathepsins during metastasis.
D Maetzel (Munich, Germany) reported on the glycosylation
status of EpCAM. Point mutation analysis of potential N-
glycosylation sites verified that all three sites in EpCAM are
modified in human epithelial cells (see Figure 1A) in contrast to
data claiming the lack of glycosylation at Asp
198 (Chong and
Speicher, 2001). Studies with tumour samples from head and neck
cancer patients indicate that EpCAM can be aberrantly glycosy-
lated on tumour cells (Pauli et al, 2003). The nature and functional
implications of these carbohydrate modifications awaits further
analysis.
EpCAM AS ONCOGENIC SIGNALLING PROTEIN
As reviewed by W Gillanders (St Louis, USA), EpCAM over-
expression on breast cancer cell lines is mandatory for prolifera-
tion, migration, and invasiveness of tumour cells (Osta et al, 2004).
Knockdown of EpCAM expression by specific short interfering
RNA had profound effects on the expression of certain genes.
Although expression of a-catenin mRNA was enhanced, EpCAM
knockdown reduced expression of c-myc, cyclin D and survivin,
supporting a proliferative signalling activity of overexpressed
EpCAM.
A highlight of the symposium was new data presented by M
Munz (Munich, Germany, manuscript submitted) that unravelled
the entire pathway of EpCAM signalling from the cell membrane
into the nucleus. Epithelial-specific cell adhesion activation
molecule signalling was found induced either by soluble EpCAM
or through zones of cell–cell contact, suggesting that oligomerisa-
tion is a trigger for EpCAM signalling. These signals led to cleavage
of EpCAM by proteases, releasing an intracellular peptide termed
EpIC. Involvement of proteases in EpCAM signalling was
supported by both their co-precipitation with EpCAM and by the
inhibitory effects of specific small molecule protease inhibitors,
which also reduced EpCAM-mediated gene expression events.
Two-hybrid screening identified adaptor proteins as intracel-
lular receptors for EpIC allowing the formation of a multiprotein
signalling complex shown to be involved in target gene induction
Table 1 EpCAM-directed immunotherapeutic approaches in clinical development
Therapeutic
(Alternative Name) Class
Ongoing or recently
completed trials Dosing Company
Catumaxomab
(Removab
s)
Trispecific antibody; mouse IgG2a/
rat IgG2b hybrid
Phase II/III in ovarian cancer
Phase II in gastric cancer
i.p., escalating dose from
10–200mg
Trion Pharma/Fresenius
Biotech
Proxinium
s Vivendium
s
(VB4-845)
Immunotoxin; single-chain antibody
pseudomonas exotoxin fusion
Phase II/III in head and neck cancer
Phase I/II in bladder cancer
Intratumoral; up to
4mgday
 1
Intra-bladder
Viventia
IGN-101 (edrecolomab) Vaccine for induction of anti-
idiotypic antibody response
Phase II in various adenocarcinoma
Phase II/III in non-small cell lung
cancer
Multiple s.c.; 0.5mg Aphton
Adecatumumab (MT201) Fully human IgG1 mAb Phase II in metastatic breast and
early-stage prostate cancer
Phase I in metastatic breast, plus
Taxotere
i.v.; 2 and 6mgkg
 1;2 -
week interval
i.v.; 4 and 13mgkg
 1 3-
week interval
Micromet, Inc./Serono
ING-1 Human engineered IgG1 mAb Phase I in various adenocarcinoma i.v. or s.c. ; up to 6 
1mgkg
 1 (MTD)
Xoma, Inc.
EMD 273 066 (huKS-IL2) Fusion of humanized mAb KS1/4
with human IL-2
Phase I in hormone-refractory
prostate cancer
i.v.; up to 6.4mgm
2day
 1
(MTD)
Lexigen, Inc./Merck KGa
Various Vaccines Extracellular domain of EpCAM;
EpCAM encoding viruses
Phase I trials in various
adenocarcinoma
s.c. Academically sponsored
EpCAM¼epithelial cell adhesion activating molecule; i.p¼intraperitoneal; i.v¼intravenous; MTD¼maximum tolerated dose; s.c¼subcutaneous.
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sand growth-promoting effects. Multicolour immunofluorescence
analysis impressively demonstrated cytoplasmic/nuclear redistri-
bution of all the involved proteins depending on EpCAM
signalling. An antibody to EpIC was found to give a speckled
staining inside the nucleus of stimulated cells, indicating an
association of the EpCAM signalosome with specific chromatin
sites. With specific inhibitors of EpCAM cleavage, a pharmacolo-
gical means is given to interfere with EpCAM signalling in tumour
cells. Future studies are needed to understand how EpCAM
signalling is regulated in normal vs malignant cells.
Support for a mitogenic signalling of EpCAM came from
experiments in which EpCAM was overexpressed under control
of the MMTV LTR in mammary glands of transgenic mice (S
Litvinov, Amsterdam, The Netherlands). Glands of virgin 1.5-year-
old mice had hugely overgrown ducts that were dilated, showed
extensive budding, and produced milk proteins. Reduced apopto-
sis and a high-level Bcl-2 expression, as well as increased
proliferation (Ki67 marker), were noted.
EpCAM ON DTC
Disseminated tumour cells (DTC) can be detected in bone marrow
of cancer patients using a pan-cytokeratin (CK) antibody, as
reviewed by K Pantel (Hamburg, Germany). Numerous studies
have shown that the occurrence and number of CK
þ DTC in bone
marrow of various cancers correlates with a poor survival
prognosis of patients (Braun et al, 2005; Janni et al, 2005; Muller
and Pantel, 2005; Muller et al, 2005; Pantel and Woelfle, 2005). A
proportion of DTC in bone marrow is also positive for EpCAM and
their depletion in breast cancer patients has been demonstrated
by anti-EpCAM monoclonal antibody edrecolomab. Occurrence of
EpCAM
þ DTC in lymph nodes and in peripheral blood samples
of cancer patients has also been shown to correlate with poor
survival. A validated platform for detection and quantitation of
circulating EpCAM
þ tumour cells (CTC) has been established and
is now being explored for therapy monitoring (Rao et al, 2005;
Woelfle et al, 2005). The employment of enrichment beads using
an anti-EpCAM antibody in addition to an anti-HER-2 antibody,
did not apparently isolate CTC with an altered phenotype and
expression profile.
C Klein (Munich, Germany), a pioneer in the study of single
DTC for genomic aberrations and transcriptional patterns (Klein
et al, 2002a,b), investigated subpopulations of tumour cells as
found in bone marrow biopsies of prostate cancer patients. In
these patients staged as M0 (no metastasis), BR (biochemical PSA
relapse), and M1 (established metastasis), EpCAM-positivity of
bona fide tumour cells significantly increased with progression
from M0 to BR, and further to M1 stages from 9 to 16–33%.
Epithelial-specific cell adhesion activation molecule
þ tumour cells
had double the amount of chromosomal aberrations than CK
þ
tumour cells, and these aberrations affected different chromosome
locations. There was only a small overlap between EpCAM
þ and
CK
þ DTC populations of 9.5%. Epithelial-specific cell adhesion
KCLVMKAEMNGSKLGRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNG–TSTCWCVNTAGVR
PCERERASALESLAGPK---------LSGLYVPQCDEDGNYEPVQCHGSTGYCWCVDPDGEE
EpCAM65-125
Thyroglob.
EGF TY
N C
TM SP 1 50 100 150 200 250 300 314
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domain II
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B
Figure 1 Revised structural model of EpCAM. (A) Sequence homology between the second EGF-like domain of EpCAM and a repeat from human
thyroglobulin (TY). EpCAM is shown with N- (N) and C-terminus (C), signal peptide (SP), transmembrane domain (TM), N-linked carbohydrates (CHO),
EGF-like domain (EGF) and TY repeat domain (TY). Sequence identity (red amino acid residues) between EpCAM and a selected TY repeat is 54%.
Conserved exchanges are shown in blue. The cognate motif of all TY domains, QCNxCWCV, is highlighted by pink boxes. (B) Old (left) and revised domain
model of EpCAM (right). EpCAM is depicted as a tetramer showing three additional subunits with dotted lines. Structural analysis of many TY domains from
different proteins has shown that N- and C-termini are in close proximity. This is why the polypeptide chain is depicted with a bent within the TY domain
that would orient the EGF-like domain towards the cell membrane. Cleavage sites for two proteases releasing the intracellular portion of EpCAM are
indicated by red arrows, and the domain of EpCAM interacting with the listed proteins is shown by a bracket.
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sactivation molecule thus defined a subpopulation of DTC in
prostate cancer patients that – unlike CK
þ DTC – already
expanded during biochemical relapse and had a phenotype
different from that of CK
þ tumour cells.
Expression of EpCAM on DTC and CTC, which are suspected to
include early progenitor cells for metastases, is consistent with a
role of EpCAM in tumour growth and progression, and stem cell
fate. Future studies need to investigate and corroborate whether
EpCAM is a marker for highly tumorigenic cancer stem cells, as
has recently been suggested (Al-Hajj et al, 2003).
EpCAM EXPRESSION AND SURVIVAL PROGNOSIS OF
CANCER PATIENTS
Another topic of the symposium was the question why EpCAM
expression had in some tumour types a negative, in most a
seemingly neutral and in other tumour types, a positive
prognostic impact on the overall survival of patients (Table 2).
P Went (Basel, Switzerland) presented data from analyses of
hundreds to thousands of samples of prostate, lung, colon, gastric,
and renal cell cancer patient for the frequency, intensity, and
homogeneity of EpCAM expression using highly standardised
staining conditions on tissue microarrays (Went et al, 2004, 2005,
2006). On average, high-level and mostly homogenous EpCAM
expression was found on 85% of adenocarcinoma and on 72% of
squamous cell carcinoma. In prostate cancer, a subanalysis
indicated that EpCAM expression is higher on hormone-refractory
tumour tissue than on earlier stages (P¼0.015), and that there
is a decrease in EpCAM expression with increasing Gleason score
(P¼0.011). In the subgroup of pT2 adenocarcinoma of the lung,
a high EpCAM expression was correlated with a better prognosis
of patients.
G Gastl (Innsbruck, Austria) reviewed the expression of EpCAM
in human breast cancer and its strong negative correlation with
survival parameters in node-positive patients (Spizzo et al, 2004).
Efforts for standardising the immunohistochemical staining
and evaluation procedure were explained highlighting an advanced
scoring system that reflected both frequency, and intensity of
staining. A similar negative correlation between EpCAM expression
and survival as previously observed by the group for breast and
gall bladder cancer (Varga et al, 2004) was also now observed with
ampullary carcinoma of the pancreas (Fong et al, 2006) and for
squamous cell cancer of head and neck.
N Stoecklein (Duesseldorf, Germany) reported a negative
correlation between EpCAM expression and overall survival in
patients with squamous cell carcinoma of the oesophagus, a very
deadly disease with no established systemic treatment option.
Although normal epithelium showed no EpCAM expression, up to
41% of patients showed high-level expression with a strong
negative prognostic impact (P¼0.0002) (Stoecklein et al, 2006).
A number of studies aim at the understanding of the regulation
of EpCAM at the transcriptional level. These studies include
deletion analysis of the EpCAM promoter and identification of
transcription factors governing EpCAM expression (O Gires,
Munich, W Gommans, and I van der Gun, The Netherlands) and
analysis of the methylation and amplification status of the EpCAM
gene (G Spizzo, Innsbruck, Austria). No differences in promoter
methylation could be found in breast cancer vs normal tissue
samples, albeit studies in breast cancer cell lines suggested a role
for methylation in the regulation of EpCAM expression (Spizzo
et al, 2006a).
M Mitas (Charleston, USA) presented data from screening for
genes commonly expressed in metastatic lymph nodes from lung,
breast, and pancreas cancers but not in normal lymph nodes.
Epithelial-specific cell adhesion molecule and activation molecule,
TROP-2, CK8, CK19, and claudin-3 were among the few commonly
expressed genes, which fell into two clusters. Upregulation of
Ets family transcription factor Esx/Elf3 in metastatic lymph
nodes correlated well with expression of EpCAM, and is being
investigated as potential transcriptional regulator.
EpCAM-DIRECTED IMMUNOTHERAPIES UNDER
DEVELOPMENT
G Schlimok (Augsburg, Germany) reviewed the clinical develop-
ment of the anti-EpCAM mAb edrecolomab (17-1A; Panorex
s).
This well-tolerated murine IgG2a antibody, which was temporarily
marketed in Germany, showed a significant increase in overall
survival of colorectal cancer patients in the adjuvant setting in two
out of four trials (Riethmu ¨ller et al, 1994, 1998; Hempel et al, 2000;
Punt et al, 2002; Hartung et al, 2005). The speaker concluded
that despite a very benign safety profile of edrecolomab, its short
half-life, rapid neutralisation by a mouse-anti-human antibody
response, and a borderline clinical activity asks for development
of an improved mAb, ideally of human nature. H Loibner
(Vienna, Austria) reviewed clinical trials using very low doses of
edrecolomab as a subcutaneously administered vaccine, called
IGN101, for induction of an anti-idiotypic antibody response.
Virtually all patients developed humoral immune responses
against the vaccine antigen, and a reduction of circulating tumour
cells was observed in Phase I trial. A double-blind placebo-
controlled phase II trial in several carcinoma indications did not
reveal a significant impact on overall survival, but retrospective
analysis of a subgroup of the stage IV rectal cancer patients
showed a significant survival benefit (poster published at ASCO,
2005). A large double-blind placebo-controlled phase II/III trial in
adjuvant non-small-cell lung cancer (NSCLC) is ongoing.
P Baeuerle (Carlsbad, USA) described adecatumumab (MT201),
a fully human anti-EpCAM antibody (Naundorf et al, 2002) that
currently is in three ongoing clinical trials: two phase II studies
with metastatic breast cancer and early-stage prostate cancer
patients, respectively, and a phase I study testing the safety of a
combination with taxotere. A completed phase I study in
hormone-resistant prostate cancer patients has shown that the
human antibody was well tolerated at all doses tested, has not
reached a maximum tolerated dose at 6mgkg
 1, and showed no
signs of pancreatitis, which had been an issue with two high-
affinity anti-EpCAM mAbs. Preclinical examination has shown
that adecatumumab mainly acts through antibody-dependent
cellular (ADCC) and complement-dependent cytotoxicity (CDC),
and shows high antitumour activity in a lung metastasis mouse
model when equipped with a murine Fc portion of the g2A
subtype, which is better compatible with the murine immune
system than the human g1 subtype. The speaker also presented
preclinical data on MT110, a single-chain EpCAM/CD3-bispecific
Table 2 Human adeno and squamous cell carcinoma so far reported to
show a significant correlation of EpCAM expression with survival prognosis
Negative impact on overall survival
Node-positive breast cancer
Epithelial ovarian cancer
Gall bladder cancer
Cholangiocarcinoma
Ampullary pancreas cancer
Squamous cell cancer of esophagus
Squamous cell head & neck cancer
Positive impact on overall survival
Gastric cancer (stages I and II)
Clear cell renal cancer
Moderately differentiated stage II colon cancer
Non-small-cell lung cancer stage at stage pT2
EpCAM and cancer
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santibody construct of the BiTE class (Brischwein et al, 2006). In
immunodeficient mice, very low doses of MT110 led to the
eradication of established tumours derived from human cancer cell
lines mixed with human T cells, as well as ovarian cancer tissue
of patients. In the latter case, the sole source of human T cells was
the xenograft itself, indicating that MT110 can penetrate human
tumour xenografts after intravenous (i.v.) injection and reactivate
the low numbers of tumour-resident T cells to effectively eliminate
the metastatic tissue.
H Lindhofer (Munich, Germany) reviewed preclinical and
clinical data of catumaxomab, a hybrid mouse IgG2a/rat IgG2b
antibody that is trispecific for EpCAM, CD3 and -via its Fc
portion- for antigen-presenting as well as a variety of other
cytotoxic immune cells. In mouse tumour models the trioma
format shows high antitumour activity and survival of which
part is due to a vaccination effect (Lindhofer et al, 1996). When
intraperitoneally (i.p.) given to ovarian cancer patients suffering
from ascites and peritoneal carcinomatosis, a pronounced clinical
activity was observed that in a phase I trial 21 out of 23 patients
were freed of malignant ascites. A rapid clearance of essentially all
EpCAM-positive tumour cells in ascites fluid and an expansion of
T-cell numbers were observed, which was followed by a retraction
of immune cell counts.
A pivotal study of catumaxomab in ovarian cancer patients with
malignant ascites has already enroled more than 250 patients. A
phase II study is ongoing with gastric cancer patients who are
treated during gastric surgery for prevention of peritoneal
carcinomatosis. Hence, catumaxomab appears as a very promising
biological agent for the local treatment and prevention of
peritoneal carcinomatosis.
A variation of the trispecific approach was presented by G
Moldenhauer (Heidelberg, Germany). Hybrid antibodies contain-
ing one half of the EpCAM-specific antibody HEA125 and one half
of the anti-CD3 antibody OKT3 were generated by the hybrid-
hybridoma technique. Preclinical experiments showed that T cells
isolated from malignant ascites support a redirected lysis of
tumour cells in vitro by the HEA125 CD3 trispecific antibody.
Ten ovarian cancer patients were treated in a small clinical study
with a 1mg dose of antibody. Inhibition of ascites production was
observed in eight out of 10 patients. A dramatic several thousand-
fold increase in TNF-a was measured in ascites, indicating a very
strong local immune stimulation. For selective recruitment of
activated neutrophils and macrophages, a second construct was
generated using mAb HEA125 that combines the anti-EpCAM
mAb with the anti-CD64/FcgRI mAb 197. Treatment of one ovarian
cancer patient with 6 1mg HEA125 197 also reduced ascites
and CA 125. Three clinical trials are in planning stage exploring
dose escalations of HEA125 CD3 and HEA125 197 and a
combination thereof in ovarian cancer patients with malignant
ascites.
U Zangemeister-Wittke (Bern, Switzerland) reported on the
development of an EpCAM-specific immunotoxin called Prox-
inium (4D5MOC31-ETA) that currently is in a pivotal phase II/III
trial for local treatment of head & neck cancer. An earlier phase I/II
study has shown a tumour control rate of 88% in which 25% of
injected lesions showed a complete response. Median survival of
treated patients was 301 days compared with 125 days for a
historic control group. The same antibody construct is now being
developed for local treatment of bladder cancer (here called
Vicinium
s). The immunotoxin uses a stability-engineered single-
chain humanised anti-EpCAM antibody fused to a subunit of the
bacterial Pseudomonas exotoxin. The linker contains a furin
cleavage site that allows for release within the endosome of the
toxin after EpCAM binding and endocytosis. A conformational
change of the cleaved exotoxin enables its cytosolic entry and
highly efficient inhibition of the cell’s protein synthesis. A novel
EpCAM-directed immunotoxin is under development that has the
furin cleavage site replaced by a site cleaved through matrix
metalloproteinases-2 and -9, as are selectively expressed by tumour
cells. This enables a dual targeting that may increase the
immunotoxin’s therapeutic window. In vitro data support that
cell lines lacking MMP 9 and  2 are much less vulnerable to the
immunotoxin, and that specific MMP inhibitors partially protect
cells expressing the proteases from the immunotoxin. Another
EpCAM-directed therapy presented by the speaker uses liposomes
with single-chain anti-EpCAM antibodies linked via polyethylene
glycol moieties. These long-lived liposomes are being loaded with
a mix of anti-apoptotic antisense molecules specific for Bcl-2
and Bcl-XL or with doxorubicin. Xenotransplant mouse models
designed for studying the targeting of [
3H]-labelled liposomes and
antitumour activity support the usefulness and potency of this
approach and a combination of liposomes with anti-apoptotic and
chemotherapeutic payloads.
D Herlyn (Philadelphia, USA) reviewed progress on using
EpCAM as a vaccine to elicit tumour-specific T-cell and humoral
immune responses. A variety of approaches were tested in small
un-controlled clinical trials that use for vaccination an anti-
idiotypic antibody (BR3E4), the extracellular domain of EpCAM or
EpCAM encoded by an adenovirus. Evidence for specific T-cell
responses and antigen spreading could be obtained.
In summary, a fair number of EpCAM-directed immunothera-
pies are under development as therapeutics exploiting the frequent
expression of the antigen on adeno and squamous cell carcinoma
(Table 1). Although three EpCAM-directed therapies are being
developed for local administration because of adverse systemic
effects, others are being developed for systemic use.
THERAPEUTIC WINDOW OF THE EpCAM TARGET
Already 20 years ago, it had been realized that EpCAM is also
expressed on a wide range of normal epithelia (Gottlinger et al
1986). Although normal cell expression is also found for other
‘tumour-associated’ antigens being used as antibody or vaccina-
tion targets, including HER-2, EGFR, CEA, MUC-1, CD20, CD52
and CD33, this circumstance has in no other case irritated
researchers to the extent EpCAM’s expression did. Systemic
intolerability of an EpCAM-specific immunotoxin and trispecific
antibodies, and acute pancreatitis, as seen with high-affinity
EpCAM mAbs appears consistent with a collateral damage of
normal EpCAM-expressing tissue. On the other hand, edrecolomab
and adecatumumab appear well tolerated and seemingly ignore
most normal EpCAM-expressing tissues. Although EpCAM is
highly overexpressed in breast and ovarian cancers and expressed
de novo in certain squamous cell carcinoma relative to their
respective normal epithelia, EpCAM expression on colon carcino-
ma just remains at the high level of normal colonic tissue. The
basis for a therapeutic window of EpCAM-directed therapies was
thus lively debated at the symposium.
C Potten (Manchester, UK) set the stage for this discussion by
reviewing in a very comprehensive manner the epithelial
architecture, cellular dynamics, and fates of epithelial and stem
cells in small intestine. P McLaughlin (Groningen, the Nether-
lands) investigated the consequences of targeting monoclonal
antibodies to normal and tumour tissue in a transgenic murine
model expressing human EpCAM. Antibodies were administered
i.p. and murine tissue staining for bound antibodies performed
24–48h later. Doses of 1, 10, 100, and 1000mg antibody were given,
of which a 10mg dose would corresponded to 0.4mgkg
 1 in
humans. This covers well the range at which acute pancreatitis was
seen with mAb ING-1 in man (41mgkg
 1). With increasing dose,
the human EpCAM-specific IgG1 antibody USB54 stained an
increasing number of epithelial tissues in transgenic mice. At the
low 10mg dose, the staining of pancreas, kidney and small intestine
by the antibody was most prominent. Apparently, animals showed
no adverse events even at the 1-mg dose despite the apparent
EpCAM and cancer
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to epithelial cells of many organs. It is unclear whether the
co-expressed murine EpCAM in the transgenic model could
prevent cytotoxic effects of the antibody. Animal models of this
kind will in the future be helpful in deciphering the basis for a
differential effect of antibodies on normal vs tumour tissue.
The most important insights into the accessibility of EpCAM on
normal epithelia vs tumour cells may come from recent studies
identifying a number of other proteins found in close association
with EpCAM within the cell membrane. F Le Naour (Villejuif,
France) presented evidence on the interaction of EpCAM with
tetraspanins, a family of 4-transmembrane domain proteins with
diverse biological functions. One of them, CD9, was shown by
crosslinking experiments to directly bind EpCAM whereas other
proteins including ADAM10, integrins, G proteins, and a novel
CD9 binding protein (CD9P-1) were indirectly associated. Intrigu-
ingly, loss of CD9 expression correlates with metastasis (Si and
Hersey, 1993; Miyake et al, 1996; Zheng et al, 2005) and, as
reported at the symposium, a strict co-localisation of CD9 and
EpCAM, as seen for membranes of normal colonic epithelium, was
no longer found for tumour cell membranes.
M Zoeller (Heidelberg, Germany) reported an association of
EpCAM with CD44 splice variants v4–v7 and tetraspanin D6.1A.
Partial cholesterol depletion destroyed these complexes, indicating
their co-localisation within membrane microdomains. A novel
interaction of EpCAM was found with the serine-phosphorylated
version of claudin-7, a protein found in tight junctions and the
basolateral side of epithelia. Crosslinking experiments implied
that interaction with EpCAM was direct and does not require the
EGF-like and TY domain for binding (see Figure 1). Interestingly,
claudin-7 prevented EpCAM oligomerisation, which may provide
a means to suppress and control EpCAM signalling in normal
epithelial tissue. This is corroborated by a co-localisation of
EpCAM and claudin-7 in normal tissue.
The new insights into membrane protein complexes containing
EpCAM may be the key to understand both the control of EpCAM
signalling in normal vs tumour tissue and the basis for a
therapeutic window of some but not all EpCAM-directed
immunotherapies. Certain antibody epitopes on EpCAM may only
become accessible when accessory proteins are reduced on
malignant cells or when EpCAM upon high-level overexpression
outnumbers its protein partners. Subsequent oligomerisation of
EpCAM may then provide a constitutive proliferation signal for
tumour cells.
CONCLUSIONS
This meeting has provided major insights into the role of EpCAM
in cancer, and ongoing research promises to broaden this
understanding. A focus of future research will be a more detailed
understanding of EpCAM signalling in the nucleus, the regulation
of EpCAM signalling as may be controlled via interaction of
EpCAM with itself and other proteins in the plasma membrane, the
expression and role of EpCAM on normal and cancer stem cells,
and the study of clinical efficacy of a number of EpCAM-directed
immunotherapies. It is hoped that this meeting review will
stipulate more research on EpCAM and that a common name will
be adopted by the scientific community.
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